Biocryst Pharmaceuticals buy JPMorgan Chase & Co.
Start price
06.05.25
/
50%
€9.37
Target price
06.05.26
€11.51
Performance (%)
-20.88%
Price
27.02.26
€7.41
Summary
This prediction is currently active. The prediction for Biocryst Pharmaceuticals disappoints with a performance of -20.88%. This prediction currently runs until 06.05.26. The prediction end date can be changed by JPMorgan_Chase___Co_ at any time. JPMorgan_Chase___Co_ has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Biocryst Pharmaceuticals | 17.321% | 17.321% |
| iShares Core DAX® | -0,38 % | 1,09 % |
| iShares Nasdaq 100 | -0,41 % | -1,97 % |
| iShares Nikkei 225® | 1,84 % | 10,26 % |
| iShares S&P 500 | -0,71 % | 0,44 % |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread Biocryst Pharmaceuticals diskutieren
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its price target raised by analysts at JPMorgan Chase & Co. from $10.00 to $13.00. They now have an "overweight" rating on the stock.
Ratings data for BCRX provided by MarketBeat
Stopped prediction by JPMorgan_Chase___Co_ for Biocryst Pharmaceuticals
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€4.86
20.11.23
20.11.23
€9.15
20.11.24
20.11.24
44.15%
21.11.24
21.11.24
